Surakanti Sujani G, Agulnik Mark
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.
Semin Oncol. 2008 Jun;35(3):309-19. doi: 10.1053/j.seminoncol.2008.03.009.
Salivary gland tumors are a rare and clinically diverse group of neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. Numerous phase II studies with small sample sizes have assessed the activity of different cytotoxic agents, either alone or in combination. For these agents, the objective response rates are generally modest, ranging from 15% to 50%. Duration of response is typically cited in the range of 6 to 9 months. Further evaluation of novel therapies is mandated in this disease. With the emergence of molecular targeted therapy, these tumors become optimal candidates for trials of investigational drugs and established drugs for new indications. Often, salivary gland carcinomas are indolent. As such, one should wish only to treat patients with progressive disease. Study designs must incorporate stringent inclusion criteria to enable accurate reporting of disease response and stabilization, especially in the evaluation of new drugs and novel combinations. Salivary gland-focused cooperative groups are necessary in order to accrue patients to these clinical trials and establish new treatment guidelines for these patients.
涎腺肿瘤是一组罕见且临床异质性的肿瘤，占所有恶性肿瘤的比例不到1%。对于局部区域复发或转移性疾病，全身治疗是标准方法。众多小样本的II期研究评估了不同细胞毒性药物单独或联合使用时的活性。对于这些药物，客观缓解率通常不高，在15%至50%之间。缓解持续时间通常在6至9个月范围内。对于这种疾病，需要进一步评估新型疗法。随着分子靶向治疗的出现，这些肿瘤成为研究性药物和已上市药物新适应症试验的理想候选者。涎腺癌通常生长缓慢。因此，只应治疗疾病进展的患者。研究设计必须纳入严格的纳入标准，以便准确报告疾病反应和病情稳定情况，尤其是在评估新药和新联合用药时。有必要成立专注于涎腺肿瘤的协作组，以便招募患者参加这些临床试验，并为这些患者制定新的治疗指南。
